To compare the safety and efficacy of tissue plasminogen activator (TPA) administered in controlled clinical trials to that of TPA prescribed in routine clinical practice. (strokecenter.org)
The U.S. FDA has approved the clot - busting drug tissue plasminogen activator, or tPA, to be given within three hours of symptom onset, while the American Heart Association / American Stroke Association suggest it can be given up to 4.5 hours in some patients. (sciencedaily.com)
In a related editorial, Tiffany Cossey, M.D., and Nicole R. Gonzales, M.D., of The University of Texas Health Science Center at Houston, write: «Although sICH may be an uncommon occurrence, the known risk weighs heavily on the decision of clinicians to administer tPA [intravenous tissue plasminogen activator], as well as on the decisions of patients and families regarding treatment. (sciencedaily.com)